Articles Tagged With:
- 
          Steps Clinicians Can Take to Improve Contraception Options for Patients The important thing is to ensure patient autonomy in selecting a method that works best for them — even when contraception options are limited. Clinicians also can help patients obtain their desired method of birth control. 
- 
          Physicians Could Prescribe Period Pills to Patients Who Are Late But Not Tested Period pills could become a more popular contraceptive option in the future as clinicians and women explore new ways to maintain reproductive autonomy. 
- 
          The Cancer-Prevention Benefits of Opportunistic Bilateral Salpingectomies As increasing numbers of patients seek permanent contraception in the United States, it is clinically important for OB/GYNs to talk with them about an important health benefit of bilateral salpingectomy, which is a safe procedure for both permanent contraception and to prevent ovarian cancer, research shows. 
- 
          Sebetralstat Tablets (Ekterly) The U.S. Food and Drug Administration has approved sebetralstat, the first oral, on-demand treatment for acute attacks of hereditary angioedema. Sebetralstat is a selective competitive, reversible plasma kallikrein inhibitor. It is distributed by KalVista Pharmaceuticals Inc as Ekterly. 
- 
          Contemporary Cardiovascular Disease Deaths in Asian Americans An analysis of a Centers for Disease Control and Prevention database has shown the cardiovascular disease mortality rate is higher in Asian Americans than in non-Asian Americans and that this excess mortality is particularly prevalent in Filipino Americans. 
- 
          Fidaxomicin Is More Clinically Effective than Vancomycin for C. difficile Infection There is a lack of real-world data on using fidaxomicin for Clostridioides difficile infection (CDI). A retrospective, single-center study found that treatment of CDI with fidaxomicin leads to reduced clinical failure compared to oral vancomycin. 
- 
          SGLT2 Inhibitor Plus Aldosterone Antagonist for HFpEF: Safe? Efficacious? A prospective, open-label, blinded outcome crossover trial of dapagliflozin plus spironolactone vs. dapagliflozin alone in patients with heart failure with preserved or mildly reduced left ventricular ejection fraction resulted in a greater reduction in natriuretic peptides, which was accompanied by a greater decline in kidney function and a rise in serum potassium. 
- 
          ApoB vs. Lp(a): Which Is More Important for CAD Risk? In U.K. Biobank participants without known atherosclerotic cardiovascular disease or diabetes or taking lipid-lowering therapy, the risk of developing coronary artery disease is best determined by apolipoprotein B particle number, but elevated lipoprotein(a) adds significant risk, so both should be considered. 
- 
          The Proton Pump Inhibitor Use and Hypertension Link in Menopausal Women In a large study, long-term use of proton pump inhibitors in menopausal women was associated with an increased risk of developing hypertension. 
- 
          Heat-Related Illnesses in Pediatric Patients This summer has been hot and, unfortunately, many pediatric patients have sustained heat-related conditions. Providers need to be ready to quickly recognize heat-related illnesses and institute prompt and life-saving care to give each patient the chance for the best outcome. The authors comprehensively review common and life-threatening, heat-related illnesses with an emphasis on evidence-based care. 
